Everest Medicines (HKG: 1952) reported 2024 financial results, with revenue skyrocketing 142% YoY to RMB 1.707 billion (USD 247 million) driven by Nefecon (budesonide delayed-release capsules) rapid commercial uptake. The world’s first etiological treatment for IgA nephropathy became the first non-oncology drug to exceed RMB 1 billion revenue within its first year of NRDL inclusion (January 2025). Non-IFRS net loss narrowed 71% to RMB 298 million, with strong cash balance of RMB 2.731 billion (USD 395 million) supporting pipeline advancement.
Forward‑Looking Statements This brief contains forward‑looking statements regarding 2026 clinical trial initiations, NDA filings, and regulatory approvals for EVER001, VIS-101, LEROCHOL, and Cardamyst. Actual results may differ due to clinical efficacy outcomes, competitive dynamics in IgA nephropathy (sparsentan, iptacopan), and reimbursement negotiations for pipeline assets.-Fineline Info & Tech
